BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. nitric oxide metabolic process, Influenza, Breast, Pharmacogenetics, Lovastatin, IGF1)
Bookmark Forward

QuickView for b7 h1 antigen (compound)


Genetic Markers

Most Correlated Genes

  1. ADM2
  2. CXCL8
  3. LINC-PINT
  4. EGR1
  5. ULBP1
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP
  2. KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP
  3. MURARO_PANCREAS_DUCTAL_CELL
  4. KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP
  5. HALLMARK_TNFA_SIGNALING_VIA_NFKB
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. CD8+ T cells from OT-1 mice after exposure to PD-L1
  2. Colorectal cancer (HT29 & HCT116) and melanoma PES43 cells treated with Nivolumab, sPD-L1 or both
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma.
  2. Regeneration and rejuvenation of skin by a topical YAP activator.
  3. Research progress in the regulation of tumor cell PD-L1 expression by N6-methyladenosine modificatio…
  4. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway:…
  5. Machine learning predicts cancer subtypes and progression from blood immune signatures.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
  2. GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer Aft…
  3. A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
  4. Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative…
  5. Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chro…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.